Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10515723 | 0.90 | FDPS (0.51) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL11168444 | 0.87 | FDPS (0.56) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL21277060 | 0.83 | FDPS (0.53) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL6984785 | 0.82 | FDPS (0.50) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL6680541 | 0.79 | FDPS (0.53) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL1064062 | 0.79 | CYP3A4 (0.57) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL30523221 | 0.78 | FDPS (0.56) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL8468188 | 0.78 | HSP90AA1 (0.49) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL17621603 | 0.77 | FDPS (0.47) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL10883268 | 0.77 | FDPS (0.50) | FDPSHSP90AA1CYP3A4ALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1804819-A4 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | UNIV WAYNE STATE (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1804805-A2 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | WAYNE STATE UNIVERSITY (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1804819-A2 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | WAYNE STATE UNIVERSITY (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006041939-A2 | USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL THINNING IN PREPARATION FOR SURGICAL PROCEDURES ON THE ENDOMETRIAL CAVITY AND UTERUS | WAYNE STATE UNIVERSITY (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041941-A2 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | WAYNE STATE UNIVERSITY (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1534265-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | Novartis AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| EP-1492515-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004012728-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003082254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082299-A1 | IMPROVED HORMONE REPLACEMENT THERAPY | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | FDPS 4807/4885HSP90AA1 2369/4885CYP3A4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.